Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
06/2000
06/14/2000CN1053366C Chinese herbal lotion and its prepn.
06/14/2000CN1053349C Peristrophe japonica liniment and its prepn.
06/13/2000US6075151 Inhibiting bone loss or bone resorption, particularly osteoporosis, and cardiovascular-related hyperlipidemia, cardiovascular disorders
06/13/2000US6075007 Modified noggin polypeptide and compositions
06/13/2000US6075006 For treatment of arthritis, asthma, inflammation, tumoral growth, gastro intestinal hypermotility, huntington disease, neuritis, neuralgia, migraine, hypertension, incontinence of urine, urticaria, symptoms of the carcinoid syndrome
06/08/2000WO2000032776A2 Secreted amd transmembrane polypeptides and nucleic acids encoding the same
06/08/2000WO2000032773A1 Compositions and methods for increasing bone mineralization
06/08/2000WO2000032767A1 RECOMBINANT SOLUBLE Fc RECEPTORS
06/08/2000WO2000032766A1 Human vanilloid receptors and their uses
06/08/2000WO2000032584A2 Nonsteroidal antiinflammatories
06/08/2000WO2000032578A1 Benzimidazole compounds that are vitronectin receptor antagonists
06/08/2000WO2000032570A1 Hydrazine derivatives
06/08/2000WO2000032567A1 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
06/08/2000WO2000032235A1 Transport system conjugate
06/08/2000WO2000032218A1 Controlled release formulation comprising gnrh-ii
06/08/2000WO2000032217A1 Small peptides and methods for treatment of asthma and inflammation
06/08/2000WO2000032216A1 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors
06/08/2000WO2000032189A1 Celecoxib compositions
06/08/2000WO2000007629A3 Peg-urate oxidase conjugates and use thereof
06/08/2000CA2353798A1 Controlled release formulation comprising gnrh-ii
06/08/2000CA2353550A1 Small peptides and methods for treatment of asthma and inflammation
06/08/2000CA2353402A1 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
06/08/2000CA2352555A1 Transport system conjugate
06/08/2000CA2352539A1 Recombinant soluble fc receptors
06/08/2000CA2352532A1 Compositions and methods for increasing bone mineralization
06/08/2000CA2352367A1 Nonsteroidal antiinflammatories
06/08/2000CA2351321A1 Hydrazine derivatives
06/08/2000CA2347677A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/07/2000EP1006183A1 Recombinant soluble Fc receptors
06/07/2000EP1006126A2 Osteogenic peptides
06/07/2000EP1005867A2 Botulinum toxins for modulating cholinergic controlled secretions
06/07/2000EP1005545A1 Human extracellular matrix-1
06/07/2000EP1005480A1 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
06/07/2000EP1005460A1 Prostaglandin endoperoxide h synthase biosynthesis inhibitors
06/07/2000EP1005446A1 N-aroylphenylalanine derivatives
06/07/2000EP1005445A1 N-alkanoylphenylalanine derivatives
06/07/2000EP1005378A2 Semi-interpenetrating polymer networks
06/07/2000EP1005372A1 Anti-cd40l immunotoxins for the treatment of diseases
06/07/2000EP1005359A2 FRACTURE HEALING USING PTHrP ANALOGS
06/07/2000EP1005351A1 An aqueous metal bicarbonate solution and method of use
06/07/2000EP1005343A1 Use of csaid?tm compounds as inhibitors of angiogenesis
06/07/2000CN1255857A Histone containing compsn. to treat rheumatoid arthritis
06/07/2000CN1255501A Novel phosphonyl sulfonic ester compound and its medicinal compsns.
06/07/2000CN1255340A Chinese medicine for treating rheumatoid arthritis
06/06/2000US6072068 Treating glucocorticoid-dependent diseases or symptoms
06/06/2000US6071948 Treatment of diseases caused by excessive blood vessel growth
06/06/2000US6071930 Method for treating tumors using 2-aryl-naphthyridin-4-ones
06/06/2000US6071901 Treating pain, hyperalgesia and/or inflammatory conditions in which c-fibers play a pathophysiological role; inhibition of neurogenic inflammation involving the release of neuro-peptide from peripheral and central endings of sensory nerves
06/06/2000US6071722 Nucleic acids encoding a G-protein coupled 7TM receptor (AXOR-1)
06/02/2000WO2000031289A1 Use of activated trap for screening for specific inhibitor of trap and method for aiding in the identification of a compound for use in the treatment of diseases or degenerative conditions resulting in increased bone resorption
06/02/2000WO2000031266A1 Human parathyroid hormone modifications, preparation and use
06/02/2000WO2000031263A2 Gtpase associated proteins
06/02/2000WO2000031137A1 Amino-terminal modified parathyroid hormone (pth) analogs
06/02/2000WO2000031123A2 Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof
06/02/2000WO2000031113A1 INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN
06/02/2000WO2000031084A1 Prostaglandin conjugates for treating or preventing bone disease
06/02/2000WO2000031083A1 Phospholipid derivatives of non-steroidal anti-inflammatory drugs
06/02/2000WO2000031070A1 Novel benzofurane derivatives, preparation method, use as medicines and pharmaceutical compositions containing same
06/02/2000WO2000031067A1 Propanoic acid derivatives as integrin inhibitors
06/02/2000WO2000031065A1 Compounds having cytokine inhibitory activity
06/02/2000WO2000031063A1 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
06/02/2000WO2000031055A1 Chrystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione
06/02/2000WO2000031051A1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors
06/02/2000WO2000031049A1 Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors
06/02/2000WO2000031048A1 N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
06/02/2000WO2000031046A1 Novel acylguanidine derivatives, method for preparing same, application as medicines and pharmaceutical compositions containing them
06/02/2000WO2000031044A1 Iminoguanidine derivatives, preparation method, use as medicines
06/02/2000WO2000031038A1 Quinoline derivatives as nk-2 and nk-3 receptor ligands
06/02/2000WO2000031037A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
06/02/2000WO2000030681A1 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases
06/02/2000WO2000030635A1 Composition and use of rar antagonists for promoting chondrogenesis
06/02/2000WO2000030622A2 Utilisation of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases
06/02/2000WO2000014236A3 Grf analogs with increased biological potency
06/02/2000CA2352963A1 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases
06/02/2000CA2352583A1 Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors
06/02/2000CA2352261A1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors
06/02/2000CA2351872A1 Use of activated trap for screening for specific inhibitor of trap and method for aiding in the identification of a compound for use in the treatment of diseases or degenerative conditions resulting in increased bone resorption
06/02/2000CA2351865A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
06/02/2000CA2351725A1 Substituted pyrazoles as p38 kinase inhibitors
06/02/2000CA2351679A1 Prostaglandin conjugates for treating or preventing bone disease
06/02/2000CA2351361A1 Gtpase associated proteins
06/02/2000CA2350969A1 Compounds having cytokine inhibitory activity
06/02/2000CA2349721A1 N-¬4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl|-acrylamide, an irreversible inhibitor of tyrosine kinases
06/02/2000CA2349555A1 Composition and use of rar antagonists for promoting chondrogenesis
06/02/2000CA2349290A1 Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof
05/2000
05/31/2000EP1004598A2 Coated carrier materials for the purification of blood, plasma and tissues, and columns comprising said carrier materials
05/31/2000EP1004578A2 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
05/31/2000EP1004306A2 Estrogen agonists/antagonists
05/31/2000EP1003857A2 Secreted proteins and polynucleotides encoding them
05/31/2000EP1003846A1 Protease inhibitors
05/31/2000EP1003783A2 Lipoprotein-regulating medicaments
05/31/2000EP1003763A1 83 human secreted proteins
05/31/2000EP1003723A1 2-acylaminopropanamines as tachykinin receptor antagonists
05/31/2000EP1003721A1 Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases
05/31/2000EP1003542A1 Use of substances having oxytocin activity for preparation of medicaments for wound healing
05/31/2000EP1003514A1 Cyclic amine modulators of chemokine receptor activity
05/31/2000EP1003509A1 Il-8 receptor antagonists
05/31/2000EP1003504A2 Indole derivatives and their use as mcp-1 antagonists
05/31/2000EP1003497A1 Il-8 receptor antagonists
05/31/2000EP0865428B1 Vitamin d analogues
1 ... 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 ... 820